The utility of squamous cell carcinoma antigen for the follow-up of patients with squamous cell carcinoma of the anal canal

Cancer. 1992 Jul 1;70(1):35-9. doi: 10.1002/1097-0142(19920701)70:1<35::aid-cncr2820700106>3.0.co;2-e.

Abstract

Background: Thirty-three patients with histologic documentation of squamous cell carcinoma (SCC) of the anal canal underwent prospective serial collection of 234 serum samples for radioimmunoassay of SCC tumor-associated antigen.

Methods: There were 23 female and 10 male patients, with a median age of 55 years. Twenty-two of the 33 patients had multimodality therapy with radiation therapy and chemotherapy as initial treatment.

Results: The median follow-up was 22 months (range, 4-52 months), with a median of 13 serum specimens per patient (range, 1-23 specimens). Twenty-eight patients currently have no evidence of disease, 4 patients are alive with disease, and 1 patient died with disease.

Conclusion: In these 33 patients, the sensitivity of the SCC tumor-associated antigen was 76%, specificity 86%, and positive predictive value 62%.

MeSH terms

  • Adult
  • Aged
  • Antigens, Neoplasm / blood*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Anus Neoplasms / blood*
  • Anus Neoplasms / immunology
  • Anus Neoplasms / therapy
  • Biomarkers, Tumor / blood*
  • Carcinoma, Squamous Cell / blood*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / therapy
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Sensitivity and Specificity
  • Serpins*

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Serpins
  • squamous cell carcinoma-related antigen